Skip to main content
SpringerLink
Log in

Cetuximab, panitumumab not cost effective for RAS WT CRC

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. folinic acid + fluorouracil + oxaliplatin

  2. folinic acid + fluorouracil + irinotecan

  3. 2015/2016 British pounds

Reference

  • Tikhonova I, et al. Cost-Effectiveness of Cetuximab and Panitumumab for First-Line RAS WT Metastatic Colorectal Cancer. 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCN113, 21 May 2016. Available from: URL: http://www.ispor.org/research_study_digest/list.asp?qs=45317

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cetuximab, panitumumab not cost effective for RAS WT CRC. PharmacoEcon Outcomes News 755, 14 (2016). https://doi.org/10.1007/s40274-016-3121-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3121-2

Search

Navigation